CytoMed Therapeutics Limited Ordinary Shares (GDTC)vsRevolution Medicines Inc (RVMD)
GDTC
CytoMed Therapeutics Limited Ordinary Shares
$1.18
+3.51%
HEALTHCARE · Cap: $15.26M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
CytoMed Therapeutics Limited Ordinary Shares generates 16% more annual revenue ($860,850 vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. GDTC earns a higher WallStSmart Score of 28/100 (F).
GDTC
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+83.0%
Fair Value
$6.12
Current Price
$1.18
$4.94 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 46.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GDTC
The strongest argument for GDTC centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 46.9% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : GDTC
The primary concerns for GDTC are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
GDTC profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
GDTC is growing revenue faster at 46.9% — sustainability is the question.
GDTC generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
GDTC scores higher overall (28/100 vs 24/100) and 46.9% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CytoMed Therapeutics Limited Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company is headquartered in Singapore.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?